Effects of Cetoleic Acid on Atherosclerosis (Ketolinsyre's Effekt på Aterosklerose)

Last updated: January 14, 2025
Sponsor: Oslo University Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Atherosclerosis

High Cholesterol (Hyperlipidemia)

Diabetes Prevention

Treatment

Cetoleic acid

Control oil

Clinical Study ID

NCT06172335
605236
  • Ages 20-70
  • All Genders

Study Summary

In this Randomized Controlled Trial (RCT) we want to study the effect of an oil with high concentrations of cetoelic acid (C22:n1-11) (intervention) compared to supplements with a low concentration of cetoleic acid (control), but with equivalent content of EPA og DHA, on plasma levels of epa and dha as well as atherosclerotic markers, glucose, c-peptide and triglycerides in a patient group with a metabolically unfavorable phenotype.

Our primary endpoints are changes in the concentration of EPA and DHA in plasma.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Triglycerides > 1.7 mmol/L

  • Waist measurement > 80 cm (women) and > 94 cm (men)

Exclusion

Exclusion Criteria:

  • Chronic disease (liver/kidney/metabolism)

  • Ongoing active cancer treatment

  • Excessive alcohol consumption (>40g/day)

  • Pregnant/breastfeeding or planned pregnancy during the intervention

  • High intake of fish (>3 weekly meals)

  • Level of free thyroxine (T4) and triiodothyronine (T3) outside reference ranges.

  • Hypertension (≥ 160/ 100 mmHg)

  • Total cholesterol > 7.8 mmol/L

  • Blood donation during the intervention period

  • Difficulty following the protocol

  • Smoking or sniffing

  • Regular use (> 1 day/week) of anti-inflammatory drugs

  • Regular use of omega-3 supplements/cod liver oil

  • Drug use other than stable use of statins, hypertension drugs (Ca antagonists,diuretics and beta blockers).

  • Hormonal treatment excluding stable use of thyroxine and birth controlpills/contraceptive rod

Study Design

Total Participants: 70
Treatment Group(s): 2
Primary Treatment: Cetoleic acid
Phase:
Study Start date:
January 03, 2024
Estimated Completion Date:
December 31, 2027

Study Description

This is a randomized double-blinded controlled trial (randomized 1:1). Study population: men and women 20-70 years with a metabolically unfavorable phenotype defined as: triglycerides > 1.7 mmol/L and waist measurement > 80 cm (women) and > 94 cm (men).

Study design:

  • 3 weeks run-in-period where all participants consume control capsules every morning.

  • Randomization intervention: control (1:1). All participants consume their capsules (control or intervention) for 4 weeks.

The intervention oil is consists of an oil high in cetoleic acid and the control oil is low in cetoleic acid. Both the intervention oil and the control oil are a mix of different oils; fish oils, olive oil, "high-oleic sunflower oil" and rapeseed oil so that the content of EPA, DHA and ALA is similar in the two oils.

Power calculation and sample size:

It was expected a difference of 15% in n-3 between the groups after the intervention (Østbye et al. 2019, doi:10.1017/S0007114519001478).

The level of significance was set to 5% (two-sided) and the power to 80%. A total of thirty-eight subjects were required to participate in the study, but a high dropout rate was expected (20%) and it was considered necessary to include a total of seventy (n=70) subjects (thirty-five per arm).

Connect with a study center

  • Oslo University Hospital

    Oslo,
    Norway

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.